EDITOR—In their editorial on intrapleural streptokinase for pleural infection Bouros and Light raise several points about the results of the MIST1 trial.12

They say that a treatment effect may have been overlooked since MIST1 enrolled a representative population of patients with pleural infection, including those with late “organised” disease. The analysis in the primary publication describing our trial result shows that this is not true.2 In the …